BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 14959470)

  • 21. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
    Schuster H; Barter PJ; Stender S; Cheung RC; Bonnet J; Morrell JM; Watkins C; Kallend D; Raza A;
    Am Heart J; 2004 Apr; 147(4):705-13. PubMed ID: 15077101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
    Ballantyne CM; Bertolami M; Hernandez Garcia HR; Nul D; Stein EA; Theroux P; Weiss R; Cain VA; Raichlen JS
    Am Heart J; 2006 May; 151(5):975.e1-9. PubMed ID: 16644314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia.
    Park S; Kang HJ; Rim SJ; Ha JW; Oh BH; Chung N; Cho SY
    Clin Ther; 2005 Jul; 27(7):1074-82. PubMed ID: 16154486
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quality and efficiency of statin prescribing across countries with a special focus on South Africa: findings and future implications.
    Godman B; Bishop I; Campbell SM; Malmström RE; Truter I
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):323-30. PubMed ID: 25338546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Berberine Alone or Combined with Statins for the Treatment of Hyperlipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.
    Zhang LS; Zhang JH; Feng R; Jin XY; Yang FW; Ji ZC; Zhao MY; Zhang MY; Zhang BL; Li XM
    Am J Chin Med; 2019; 47(4):751-767. PubMed ID: 31094214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
    Ohsfeldt RL; Gandhi SK; Fox KM; Stacy TA; McKenney JM
    Am J Manag Care; 2006 Nov; 12(15 Suppl):S412-23. PubMed ID: 17112329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evolutions in both co-payment and generic market share for common medication in the Belgian reference pricing system.
    Fraeyman J; Verbelen M; Hens N; Van Hal G; De Loof H; Beutels P
    Appl Health Econ Health Policy; 2013 Oct; 11(5):543-52. PubMed ID: 24062144
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidemiology and economics of statin use.
    Feely J; Bennett K
    Ir Med J; 2008 Jun; 101(6):188-91. PubMed ID: 18705057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
    Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
    Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Moving from A to Z: successful implementation of a statin switch program by a large physician group.
    Sy FZ; Choe HM; Kennedy DM; Standiford CJ; Parsons DM; Bruhnsen KD; Stevenson JG; Bernstein SJ
    Am J Manag Care; 2009 Apr; 15(4):233-40. PubMed ID: 19355796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost efficiency and formulary considerations for statin therapy.
    Killilea T; Funk L
    Am J Manag Care; 2006 Oct; 12(11 Suppl):S325-31. PubMed ID: 17042675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A case of simvastatin-associated pancreatitis and review of statin-associated pancreatitis.
    Johnson JL; Loomis IB
    Pharmacotherapy; 2006 Mar; 26(3):414-22. PubMed ID: 16503723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
    Hou R; Goldberg AC
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation.
    Aliabadi AZ; Mahr S; Dunkler D; Grömmer M; Zimpfer D; Wolner E; Grimm M; Zuckermann AO
    Transplantation; 2008 Dec; 86(12):1771-6. PubMed ID: 19104420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effect of long-term cardiac training on lipids concentration in patients with chronic heart ischemic disease treated with simvastatin].
    Kałka D; Sobieszczańska M; Kopka L; Marciniak W; Zawadzka-Bartczak E; Bak A; Popielewicz-Kautz A; Korzeniowska J; Janczak J; Adamus J
    Pol Merkur Lekarski; 2007 Feb; 22(128):101-6. PubMed ID: 17598652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis.
    Sicras-Mainar A; Sánchez-Álvarez L; Navarro-Artieda R; Darbà J
    Lipids Health Dis; 2018 Dec; 17(1):277. PubMed ID: 30522491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation.
    Crespo-Leiro MG; Paniagua MJ; Marzoa R; Grille Z; Naya C; Flores X; Rodriguez JA; Mosquera V; Franco R; Castro-Beiras A
    Transplant Proc; 2008 Nov; 40(9):3060-2. PubMed ID: 19010194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance.
    Ruisinger JF; Backes JM; Gibson CA; Moriarty PM
    Am J Cardiol; 2009 Feb; 103(3):393-4. PubMed ID: 19166695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia.
    Jones PH; McKenney JM; Karalis DG; Downey J
    Am Heart J; 2005 Jan; 149(1):e1. PubMed ID: 15660024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.